ICI-based therapy may improve overall survival in patients with primary pulmonary choriocarcinoma
Immunotherapy may extend life for men with rare lung cancer
This case report and literature review examines the management of primary pulmonary choriocarcinoma in a male patient. The authors suggest t…
A rare and aggressive lung cancer in men is showing signs of better survival when treated with immunotherapy drugs.
Camrelizumab plus chemotherapy is cost-effective for first-line treatment of advanced squamous non-small-cell lung cancer
Immune Checkpoint Inhibitors Show Cost-Effectiveness for Lung Cancer Treatment
This network meta-analysis evaluates the cost-effectiveness of six immune checkpoint inhibitor-based first-line therapies combined with chem…
New analysis shows specific immune checkpoint inhibitor combinations may be more cost-effective than chemotherapy for advanced lung cancer p…
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Case report of penpulimab, nab-paclitaxel, and anlotinib in porocarcinoma
Immunotherapy-Chemo Mix Shows Promise Against Stubborn Skin Cancer
This case report and literature review describes a 78-year-old female with porocarcinoma treated with penpulimab plus nab-paclitaxel, then a…
• A rare skin cancer slowed with immunotherapy plus chemo • Helps patients with porocarcinoma lacking treatment options • Still experimental
TQB2618 plus penpulimab shows 52% response in PD-1 refractory Hodgkin lymphoma
A New Drug Duo Revives Hope for Hodgkin Lymphoma After Immunotherapy Fails
A phase Ib single-arm trial in 21 Chinese patients with PD-1/PD-L1 inhibitor-refractory classic Hodgkin lymphoma found TQB2618 plus penpulim…
A new two-drug combination revived hope for Hodgkin lymphoma patients who failed prior immunotherapy, achieving a 52% response rate in early…
Penpulimab plus chemotherapy significantly improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma
New drug plus chemo delays cancer growth in advanced nasopharyngeal cases
This randomized, double-blind phase 3 trial evaluated penpulimab combined with cisplatin/carboplatin and gemcitabine versus placebo plus che…
Adding penpulimab to chemotherapy delays cancer growth by nearly three months in advanced nasopharyngeal cases, offering new hope for patien…